MedPath

Give Kids a Chance Act Aims to Accelerate Pediatric Drug Development

• The Give Kids a Chance Act (H.R. 3433) has unanimously passed the House of Representatives, marking a significant step in addressing childhood cancer and rare diseases. • The Act reauthorizes the FDA’s pediatric priority voucher program for five years, incentivizing the development of innovative drugs for children. • It mandates pharmaceutical companies to conduct pediatric trials with drug combinations, aligning pediatric research practices with those for adults. • The legislation also strengthens the FDA's enforcement capabilities to ensure timely completion of pediatric studies, preventing delays in drug availability.

The Give Kids a Chance Act (H.R. 3433), a bipartisan bill aimed at improving access to innovative treatments for children with cancer and rare diseases, has unanimously passed the House of Representatives. This legislation represents the most comprehensive effort in over a decade to address critical gaps in pediatric drug development.
Representative Anna G. Eshoo (CA-16), a key proponent of the bill, emphasized its potential to save children's lives by ensuring access to cutting-edge therapies. The Act focuses on several key areas to accelerate the development and availability of pediatric drugs.

Key Provisions of the Act

The Give Kids a Chance Act includes several provisions designed to enhance pediatric drug development:
  • Reauthorization of Pediatric Priority Review Voucher Program: The Act reauthorizes the FDA's pediatric priority voucher program for five years. This program incentivizes pharmaceutical companies to develop new drugs for children by offering a voucher that can be used to expedite the review of another drug.
  • Combination Drug Trials: The legislation directs pharmaceutical companies to conduct pediatric trials using combinations of drugs, mirroring the standard practice in adult oncology and other therapeutic areas. This will allow for more effective treatment strategies tailored to children.
  • Enhanced FDA Enforcement: The Act strengthens the FDA's enforcement capabilities to ensure that pediatric studies are completed on time. This provision aims to prevent delays in the availability of drugs for children due to incomplete studies.
  • Dedicated Funding for Pediatric Research: The legislation dedicates existing funds for pediatric research through the NIH’s Best Pharmaceuticals for Children Act Program for three years, further supporting research efforts.
By addressing these critical areas, the Give Kids a Chance Act seeks to accelerate the development of innovative treatments and therapies for children with cancer and rare diseases, ultimately improving their chances of survival and quality of life.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Recent Advances in Medical Treatments and Regulatory Approvals

The past months have seen significant progress in medical treatments and regulatory approvals, including new therapies for Alzheimer's disease, bladder cancer, and atopic dermatitis, as well as updates on rare disease innovation and biosimilar products.

Pediatric RISE Program Shows Promise in Alleviating Financial Burden for Childhood Cancer Patients

A pilot study of Pediatric RISE (Resource Intervention to Support Equity) demonstrates feasibility and value in supporting low-income families with children undergoing cancer treatment.
The program provides direct cash transfers, leading to reduced family-reported hardships related to food, housing, utilities, and transportation.

FDA Approves BridgeBio's Drug for Rare Heart Condition, Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The FDA has approved BridgeBio's drug for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and often fatal heart condition.
This approval marks a significant advancement in treating ATTR-CM, offering a new therapeutic option for patients with this disease.

Promising Pathway Act 2.0 Aims to Expedite Rare Disease Drug Approvals

The Promising Pathway Act (PPA) 2.0, under consideration in both the US House and Senate, seeks to establish a time-limited conditional approval pathway for drugs targeting rare, rapidly progressive diseases.
The proposed legislation would allow the FDA to grant initial conditional approval for two years, renewable up to eight years, for eligible drugs addressing substantial unmet needs.

FDA Expands Methotrexate Approval for Pediatric ALL and Juvenile Idiopathic Arthritis

The FDA has expanded the approval of methotrexate (Jylamvo) to include pediatric patients with acute lymphoblastic leukemia (ALL).
The expanded approval also covers the use of methotrexate in pediatric patients with polyarticular juvenile idiopathic arthritis.

FDA Expands Methotrexate Approval for Pediatric Acute Lymphoblastic Leukemia

The FDA has expanded the approval of methotrexate (Jylamvo) to include pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.
The recommended starting dose for methotrexate in pediatric ALL is 20 mg/m2 once weekly, with regular monitoring of absolute neutrophil counts and platelet counts for dose adjustments.

House Introduces Bill for Conditional FDA Approval Pathway for Rare Disease Drugs

A revised version of the Promising Pathways Act 2.0, seeking a conditional FDA approval pathway for rare disease drugs, has been introduced in the House.
The bill aims to mandate coverage of these drugs without cost-sharing, potentially impacting access and affordability for patients with rare diseases.

Novartis Loses Bid to Block Generic Entresto, J&J Cuts Neurology Programs

A U.S. judge ruled that the FDA can approve generic versions of Novartis' heart failure drug Entresto, which generated over $6 billion in revenue last year.
Novartis plans to appeal the decision, but the launch of the generic version still faces other legal challenges.

Pediatric Drug Testing Under PREA: An Analysis of Drugs Approved 2015-2021

A recent study evaluates the impact of the Pediatric Research Equity Act (PREA) on drugs approved between 2015 and 2021, revealing the extent of pediatric testing.
The analysis highlights that while PREA mandates pediatric testing, exemptions and deferrals are common, impacting the availability of pediatric-specific drug information.

FDA Approves Roche's Subcutaneous Multiple Sclerosis Treatment and Eli Lilly's Eczema Drug

The FDA has approved Roche's subcutaneous injection for multiple sclerosis, offering an alternative to intravenous administration and potentially expanding treatment options.
Eli Lilly's new eczema drug has received FDA approval for use in adults and children over 12, providing a new therapeutic option for this patient population.

Reference News

[1]
Eshoo Bill to Improve Pediatric Drugs Passes House Unanimously
eshoo.house.gov · Sep 24, 2024

Rep. Anna G. Eshoo's H.R. 3433, the Give Kids a Chance Act, unanimously passed the House, aiming to enhance pediatric ca...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy